Obsidian, Galera to Advance Cell Therapy Following Reverse Merger

Why It Matters

The merger provides Obsidian with substantial capital to advance a differentiated TIL therapy, while giving investors exposure to a potentially high‑value oncology platform as the market seeks alternatives to CAR‑T and checkpoint drugs.

Key Takeaways

• OBX-115 TIL therapy avoids toxic interleukin‑2, outpatient biopsy.
• $350 M private placement funds operations through 2028.
• Merger gives Galera shareholders 1.8% and investors 45% stake.
• OBX-115 trial readouts slated for 2027 melanoma and lung cancer.
• Nasdaq ticker “OBX” launches post‑merger, led by CEO Jagasia.

Pulse Analysis

The emergence of tumor‑infiltrating lymphocyte (TIL) therapies marks a new frontier in adoptive cell immunotherapy, offering a distinct mechanism from CAR‑T and checkpoint inhibitors. Following Iovance Biotherapeutics’ FDA approval of Amtagvi, Obsidian’s OBX-115 aims to improve tolerability by eliminating the need for high‑dose interleukin‑2 and enabling minimally invasive, outpatient cell harvesting. This design could broaden patient eligibility and reduce hospital stays, positioning OBX-115 as a potentially more scalable and cost‑effective option for treating advanced melanoma and non‑small cell lung cancer.

Financially, the reverse merger with Galera unlocks a $350 million private placement, dramatically expanding Obsidian’s balance sheet and extending its runway to late 2028. The capital infusion will support ongoing Phase II melanoma data readouts and early‑stage lung‑cancer results slated for 2027, milestones that could trigger significant valuation uplift. Galera’s contribution—both cash and a retained pipeline of small‑molecule radioprotectors—adds diversification, while its shareholders receive a modest equity stake, aligning interests across the combined entity.

For investors, the transaction signals confidence in TIL platforms as a growth engine within oncology biotech. The Nasdaq listing under “OBX” provides greater liquidity and visibility, potentially attracting institutional capital seeking exposure to next‑generation immunotherapies. As the sector grapples with pricing pressures and manufacturing complexities, OBX-115’s outpatient‑friendly approach may address key market pain points, making the combined company a compelling candidate for partnership or acquisition discussions in the coming years.